Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market.
The global market for Sexual Dysfunction Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sexual Dysfunction Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Sexual Dysfunction Drugs by region & country, by Type, and by User.
The Sexual Dysfunction Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sexual Dysfunction Drugs.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
Segment by Type:
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Sexual Dysfunction Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Sexual Dysfunction Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Sexual Dysfunction Drugs in country level. It provides sigmate data by Type, and by User for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Sexual Dysfunction Drugs Product Introduction
1.2 Global Sexual Dysfunction Drugs Market Size Forecast
1.2.1 Global Sexual Dysfunction Drugs Sales Value (2019-2030)
1.2.2 Global Sexual Dysfunction Drugs Sales Volume (2019-2030)
1.2.3 Global Sexual Dysfunction Drugs Sales Price (2019-2030)
1.3 Sexual Dysfunction Drugs Market Trends & Drivers
1.3.1 Sexual Dysfunction Drugs Industry Trends
1.3.2 Sexual Dysfunction Drugs Market Drivers & Opportunity
1.3.3 Sexual Dysfunction Drugs Market Challenges
1.3.4 Sexual Dysfunction Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Sexual Dysfunction Drugs Players Revenue Ranking (2023)
2.2 Global Sexual Dysfunction Drugs Revenue by Company (2019-2024)
2.3 Global Sexual Dysfunction Drugs Players Sales Volume Ranking (2023)
2.4 Global Sexual Dysfunction Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Sexual Dysfunction Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Sexual Dysfunction Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Sexual Dysfunction Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Sexual Dysfunction Drugs
2.9 Sexual Dysfunction Drugs Market Competitive Analysis
2.9.1 Sexual Dysfunction Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Sexual Dysfunction Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sexual Dysfunction Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral Therapy
3.1.2 Intracavernosal Therapy
3.1.3 Hormonal Therapy
3.1.4 Transurethral Therapy
3.2 Global Sexual Dysfunction Drugs Sales Value by Type
3.2.1 Global Sexual Dysfunction Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Sexual Dysfunction Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Sexual Dysfunction Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Sexual Dysfunction Drugs Sales Volume by Type
3.3.1 Global Sexual Dysfunction Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Sexual Dysfunction Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Sexual Dysfunction Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Sexual Dysfunction Drugs Average Price by Type (2019-2030)
4 Segmentation by User
4.1 Introduction by User
4.1.1 Male
4.1.2 Female
4.2 Global Sexual Dysfunction Drugs Sales Value by User
4.2.1 Global Sexual Dysfunction Drugs Sales Value by User (2019 VS 2023 VS 2030)
4.2.2 Global Sexual Dysfunction Drugs Sales Value, by User (2019-2030)
4.2.3 Global Sexual Dysfunction Drugs Sales Value, by User (%) (2019-2030)
4.3 Global Sexual Dysfunction Drugs Sales Volume by User
4.3.1 Global Sexual Dysfunction Drugs Sales Volume by User (2019 VS 2023 VS 2030)
4.3.2 Global Sexual Dysfunction Drugs Sales Volume, by User (2019-2030)
4.3.3 Global Sexual Dysfunction Drugs Sales Volume, by User (%) (2019-2030)
4.4 Global Sexual Dysfunction Drugs Average Price by User (2019-2030)
5 Segmentation by Region
5.1 Global Sexual Dysfunction Drugs Sales Value by Region
5.1.1 Global Sexual Dysfunction Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Sexual Dysfunction Drugs Sales Value by Region (2019-2024)
5.1.3 Global Sexual Dysfunction Drugs Sales Value by Region (2025-2030)
5.1.4 Global Sexual Dysfunction Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Sexual Dysfunction Drugs Sales Volume by Region
5.2.1 Global Sexual Dysfunction Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Sexual Dysfunction Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Sexual Dysfunction Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Sexual Dysfunction Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Sexual Dysfunction Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Sexual Dysfunction Drugs Sales Value, 2019-2030
5.4.2 North America Sexual Dysfunction Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Sexual Dysfunction Drugs Sales Value, 2019-2030
5.5.2 Europe Sexual Dysfunction Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Sexual Dysfunction Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Sexual Dysfunction Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Sexual Dysfunction Drugs Sales Value, 2019-2030
5.7.2 South America Sexual Dysfunction Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Sexual Dysfunction Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Sexual Dysfunction Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Sexual Dysfunction Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Sexual Dysfunction Drugs Sales Value
6.2.1 Key Countries/Regions Sexual Dysfunction Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Sexual Dysfunction Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Sexual Dysfunction Drugs Sales Value, 2019-2030
6.3.2 United States Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.4 Europe
6.4.1 Europe Sexual Dysfunction Drugs Sales Value, 2019-2030
6.4.2 Europe Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.5 China
6.5.1 China Sexual Dysfunction Drugs Sales Value, 2019-2030
6.5.2 China Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.6 Japan
6.6.1 Japan Sexual Dysfunction Drugs Sales Value, 2019-2030
6.6.2 Japan Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Sexual Dysfunction Drugs Sales Value, 2019-2030
6.7.2 South Korea Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Sexual Dysfunction Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
6.9 India
6.9.1 India Sexual Dysfunction Drugs Sales Value, 2019-2030
6.9.2 India Sexual Dysfunction Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Sexual Dysfunction Drugs Sales Value by User, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Sexual Dysfunction Drugs Product Offerings
7.1.5 Pfizer Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Information
7.2.2 GlaxoSmithKline Introduction and Business Overview
7.2.3 GlaxoSmithKline Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 GlaxoSmithKline Sexual Dysfunction Drugs Product Offerings
7.2.5 GlaxoSmithKline Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck Sexual Dysfunction Drugs Product Offerings
7.3.5 Merck Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Company Information
7.4.2 Eli Lilly Introduction and Business Overview
7.4.3 Eli Lilly Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Eli Lilly Sexual Dysfunction Drugs Product Offerings
7.4.5 Eli Lilly Recent Development
7.5 AbbVie
7.5.1 AbbVie Company Information
7.5.2 AbbVie Introduction and Business Overview
7.5.3 AbbVie Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 AbbVie Sexual Dysfunction Drugs Product Offerings
7.5.5 AbbVie Recent Development
7.6 Bayer
7.6.1 Bayer Company Information
7.6.2 Bayer Introduction and Business Overview
7.6.3 Bayer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Bayer Sexual Dysfunction Drugs Product Offerings
7.6.5 Bayer Recent Development
7.7 Teva Pharmaceutical Industries
7.7.1 Teva Pharmaceutical Industries Company Information
7.7.2 Teva Pharmaceutical Industries Introduction and Business Overview
7.7.3 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Product Offerings
7.7.5 Teva Pharmaceutical Industries Recent Development
7.8 Takeda
7.8.1 Takeda Company Information
7.8.2 Takeda Introduction and Business Overview
7.8.3 Takeda Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Takeda Sexual Dysfunction Drugs Product Offerings
7.8.5 Takeda Recent Development
7.9 Apricus Biosciences
7.9.1 Apricus Biosciences Company Information
7.9.2 Apricus Biosciences Introduction and Business Overview
7.9.3 Apricus Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Apricus Biosciences Sexual Dysfunction Drugs Product Offerings
7.9.5 Apricus Biosciences Recent Development
7.10 Emotional Brain
7.10.1 Emotional Brain Company Information
7.10.2 Emotional Brain Introduction and Business Overview
7.10.3 Emotional Brain Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Emotional Brain Sexual Dysfunction Drugs Product Offerings
7.10.5 Emotional Brain Recent Development
7.11 Ivix LLX
7.11.1 Ivix LLX Company Information
7.11.2 Ivix LLX Introduction and Business Overview
7.11.3 Ivix LLX Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Ivix LLX Sexual Dysfunction Drugs Product Offerings
7.11.5 Ivix LLX Recent Development
7.12 Leadiant Biosciences
7.12.1 Leadiant Biosciences Company Information
7.12.2 Leadiant Biosciences Introduction and Business Overview
7.12.3 Leadiant Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Leadiant Biosciences Sexual Dysfunction Drugs Product Offerings
7.12.5 Leadiant Biosciences Recent Development
7.13 NexMed
7.13.1 NexMed Company Information
7.13.2 NexMed Introduction and Business Overview
7.13.3 NexMed Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 NexMed Sexual Dysfunction Drugs Product Offerings
7.13.5 NexMed Recent Development
7.14 S1 Biopharma
7.14.1 S1 Biopharma Company Information
7.14.2 S1 Biopharma Introduction and Business Overview
7.14.3 S1 Biopharma Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 S1 Biopharma Sexual Dysfunction Drugs Product Offerings
7.14.5 S1 Biopharma Recent Development
7.15 Vietstar Biomedical Research
7.15.1 Vietstar Biomedical Research Company Information
7.15.2 Vietstar Biomedical Research Introduction and Business Overview
7.15.3 Vietstar Biomedical Research Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Vietstar Biomedical Research Sexual Dysfunction Drugs Product Offerings
7.15.5 Vietstar Biomedical Research Recent Development
8 Industry Chain Analysis
8.1 Sexual Dysfunction Drugs Industrial Chain
8.2 Sexual Dysfunction Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Sexual Dysfunction Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Sexual Dysfunction Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
听
听
*If Applicable.